Stay updated with breaking news from Patients Achieved. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 ... | June 5, 2023
Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 at 12 Weeks, Indicating a Near-Total or Total Clearan...
94% of Patients Achieved a Response at 18 Months in Pivotal ZUMA-5 Trial -- -- Yescarta Reduced Risk of Death by 58% Compared to Current Therapies in Weighted Analysis of ZUMA-5 Compared to SCHOLAR-5 External Control Cohort -- -- Late-breaking Data Presented at European Hematology Association 2021 -- Kite, a Gilead Company today announced follow-up results from the pivotal ZUMA-5 trial of Yescarta ® the first and ...
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI 98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – Gilead Sciences, Inc. today announced new, … >98% of Treatment-Naïve Patients Achieved and Mainta...